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uTATE-OF-THE-ART PAPER461Aortopathies in Congenital Heart Diseasenji T. Yetman, Thomas Graham
etman and Graham review the literature regarding the incidence, biochemical pathways,
linical outcomes, and treatment modalities for aortic root dilation in patients with congenital
eart disease. Marfan syndrome is the most obvious example where a genetic defect in the
roduction of fibrillin is associated with aortic dilation and possible rupture, but many other
ongenital anomalies may also be associated with aortic dilation. Fibrillin content is also
educed in both the aorta and the pulmonary artery of patients with bicuspid aortic valve. The
ndications for surgical correction are reviewed.VIEWPOINT IEWPOINT468Dual RAS Blockade Improves Surrogate Outcomes, But May Worsen Hard End Pointsranz H. Messerli
esserli reviews the data on the efficacy of dual renin-angiotensin system (RAS) blockade
ith both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker.
ual RAS blockade results in small reductions in blood pressure and albuminuria, and
educed hospitalizations in patients with systolic dysfunction. However, the recent larger and
onger-lasting ONTARGET (Renal Outcomes With Telmisartan, Ramipril, or Both, in
eople at High Vascular Risk) trial found that dual RAS blockade was associated with an
ncreased need of dialysis. A meta-analysis of dual RAS blockade for heart failure found
igher rates of hypotension and worsened renal function with combination therapy and no
vidence of a mortality benefit. Messerli concludes that dual RAS blockade should not be
sed unless long-term studies show clear reductions in hard end points.(continued on page A-24)
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rLINICAL TRIAL471T-Wave Alternans Compared With EPS for Risk Prediction in ICD PatientsEditorial Comment
Gregory K. Feld and Paul Clopton,tto Costantini, Stefan H. Hohnloser, Malcolm M. Kirk, Bruce B. Lerman, James H. Baker II,
arathi Sethuraman, Mary M. Dettmer, David S. Rosenbaum, for the ABCD Trial Investigators
he ABCD (Alternans Before Cardioverter Defibrillator) trial mandated that patients with
n ischemic cardiomyopathy and nonsustained ventricular tachycardia on Holter recording
ndergo microvolt T-wave alternans (MTWA) testing and electrophysiologic study (EPS)
rior to implantable cardioverter-defibrillator (ICD) insertion. The primary end point was
ppropriate ICD discharge or sudden death at 1 year. The event rate in patients with 2
ormal tests was approximately 3-fold lower than in patients with 1 abnormal test and
pproximately 6-fold lower than in patients with 2 abnormal tests. The positive and negative
redictive values of MTWA and EPS were similar. Strategies employing MTWA, EPS, orp. 480 oth may identify which patients are least likely to benefit from ICD insertion.ARDIAC RESYNCHRONIZATION THERAPY483Clinical Benefit of CRT Predicted by the Magnitude of the Reduction in LVESVlaudia Ypenburg, Rutger J. van Bommel, C. Jan Willem Borleffs, Gabe B. Bleeker, Eric Boersma,
artin J. Schalij, Jeroen J. Bax
penburg and colleagues followed more than 300 patients who underwent cardiac
esynchronization therapy (CRT) to study the relationship between left ventricular (LV)
emodeling, defined as the decrease in left ventricular end-systolic volume (LVESV), and
linical outcomes. Twenty-two percent of patients were classified as super-responders (a
ecrease in LVESV 30%), 35% as responders (a decrease in LVESV of 15% to 29%), 21%
s nonresponders (a decrease in LVESV of 0% to 14%), and 22% as negative-responders (an
ncrease in LVESV). Clinical outcomes confirmed that the extent of LV remodeling was
elated to clinical outcomes including mortality and hospitalization. The extent of LV reverse
emodeling at 6 months is predictive of long-term outcome in CRT patients.(continued on page A-26)
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gRE-CLINICAL RESEARCH491Aortic Valve Cells Have Pro-Osteogenic Phenotype That Increases Calcificationiaoping Yang, David A. Fullerton, Xin Su, Lihua Ao, Joseph C. Cleveland, Jr, Xianzhong Meng
ang and colleagues isolated interstitial cells from both the aortic valve and the pulmonic
alve in explanted hearts. Aortic valve interstitial cells (AVICs) express higher levels of toll-
ike receptor (TLR)2 and TLR4 than pulmonary valve interstitial cells (PVICs) isolated from
he same human heart. Stimulating TLR2 or TLR4 promoted greater expression of pro-
nflammatory and pro-osteogenic mediators in AVICs than in PVICs. AVICs from stenotic
alves had higher levels of TLR2 and TLR4 than AVICs from normal valves. These results
uggest that TLR2 and TLR4 may play an important role in aortic valve calcification and
ubsequent stenosis.RE-CLINICAL RESEARCH501Exenatide Reduces Ischemia Reperfusion Injury in a Pig ModelPBS Exenatide
Editorial Comment
Ian G. Webb, Rupert Williams, and
Michael S. Marber, p. 511eo Timmers, José P. S. Henriques, Dominique P. V. de Kleijn, J. Hans DeVries, Hans Kemperman,
aul Steendijk, Cees W. J. Verlaan, Marjolein Kerver, Jan J. Piek, Pieter A. Doevendans,
erard Pasterkamp, Imo E. Hoefer
xenatide is a small glucagon-like peptide (GLP-1) analogue, originally derived from the
aliva of the gila monster, that may reduce apoptosis and reperfusion injury. Timmers and
olleagues randomized pigs to exenatide or placebo following 75 min of coronary artery
igation and prior to subsequent reperfusion. Exenatide reduced the infarct size from 54% to
3% of the area at risk and prevented deterioration of systolic and diastolic cardiac function.
his was associated with reduced cellular apoptosis. These data identify exenatide as a
otentially effective addition to reperfusion therapy in patients with acute myocardial
nfarction.MEETING
HIGHLIGHTSEETING HIGHLIGHTS514Highlights From the 2008 Heart Failure Society of America Meetingandeep R. Mehra, Howard A. Rockman, Barry H. Greenberg
ehra and colleagues report the highlights from the 2008 Scientific Sessions of the Heart
ailure Society of America, which was held in September 2008. Highlights included a session
ocused on the relationship of environmental factors to heart failure, including increased rates
f obesity in urban population. Several studies that were presented as late breaking clinical
rials are also summarized. The MOMENTUM (Orqis Medical Cancion System for the
nhanced Treatment of Heart Failure Unresponsive to Medical Therapy) trial identified a
roup of patients who may benefit from a percutaneously placed aortic flow assist device, and
ther trials suggested that the efficacy of long-acting carvedilol did not differ from immediate
elease and that sertraline appears safe in patients with heart failure. The development of
uidelines for heart failure management is also discussed.
